Amgen registers Phase 3 MariTide trial against semaglutide in type 2 diabetes
A new Phase 3 study comparing maridebart cafraglutide to semaglutide headlines the week, alongside two previously reported Phase 1 studies.
Amgen's most notable new filing is a large Phase 3 diabetes study pitting its obesity candidate against semaglutide, while two earlier Phase 1 records continue to advance.
- A Phase 3, open-label trial called "MARITIME-T2D-3" is recruiting to test whether maridebart cafraglutide given once monthly is non-inferior to semaglutide given once weekly in improving glycemic control in participants with type 2 diabetes who are receiving metformin, with or without an SGLT-2 inhibitor.1 The study has an estimated enrollment of 1300 participants1 and lists change from baseline in HbA1c at Week 68 as the primary outcome, measured for non-inferiority.1 The trial began on 2026-10-16 and was first posted on 2026-10-08.
- A Phase 1 crossover study comparing extended-release and immediate-release formulations of apremilast in healthy participants is not yet recruiting, with an estimated start of 2026-11-18 and enrollment of 114 participants2 planned.
- A separate Phase 1 study assessing the pharmacokinetics of maridebart cafraglutide after switching from weekly GLP-1RA in participants living with overweight or obesity3 is recruiting, with an estimated start of 2026-11-13 and enrollment of 180 participants3 across 9 U.S. sites.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.